XPENG-MOTORS
9.6.2020 19:04:05 CEST | Business Wire | Press release
Xpeng Motors, a leading electric vehicle and technology company, today reveals an exclusive inside view into its self-built wholly-owned factory in Zhaoqing, Guangdong Province.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005686/en/
The Zhaoqing Xpeng Motors Intelligent Industrial Park, birthplace of the super-long range sports sedan Xpeng P7, was built over a period of 15 months. On May 19, 2020 the factory received the official production license from China’s Ministry of Industry and Information Technology.
Find the pictures and videos revealing the interior of the factory here: https://drive.google.com/drive/folders/1RzxP_eVWDWwVdnfaYTt01G7hn3F-ZZeS?usp=sharing
“We are deeply proud of our achievement as a young company, in building our own wholly-owned smart manufacture base at Zhaoqing,” said He Xiaopeng, Chairman and CEO of Xpeng Motors.
“Xpeng is now the only new smart EV maker in China that has both self-owned and contracted plants. We are a firm believer that manufacturing is the foundation of smart cars. Only when you build solid powertrain and vehicle hardware, can you differentiate with data operation, autonomous driving and connectivity software,” He added.
“This not only gives us optimal insight into and control over our production process, it also demonstrates our capabilities in successfully managing our supply chain and executing major projects. This is a great base for future development in intelligent vehicle design and manufacture,” He concluded.
Spanning a planned area of 3,000 acres (2 million square metres), it has five cutting-edge workshops including stamping, welding, painting, final assembly, and battery pack production.
The factory is run by a 600-member professional team. 74% of the engineers are with 5+ year working experience with 78% joined from leading OEMs.
Stamping Workshop
The stamping workshop is 100% automated. Steel plates are stamped and formed on the 6,600-ton large CNC (computer numerical control) automatic stamping production line, delivering as many as 12 pieces per minute, higher than the 10% industry average, with a precision range as narrow as 0.1 millimeter.
Equipped with an industry-leading information system, the production process is highly open and transparent, with real-time monitoring of processing parameters to ensure high quality consistency.
Welding Workshop
The Zhaoqing welding workshop is equipped with 210 ABB industrial robots, meticulously performing multiple processes including gluing, welding and aluminum plate riveting. Tier-1 and Tier-2 final assemblies reach a 100% automation rate, with the capability to manufacture steel-aluminum hybrid vehicle bodies.
The factory’s self-adaptive medium frequency welding machine achieves 30% energy saving, while the advanced visual gluing system yields gluing accuracy as fine as 0.5 millimeter.
Painting Workshop
Sophisticated styling requires exceptional painting techniques. The Zhaoqing factory’s thin film pretreatment and cathode electrophoretic technology effectively reduces wastewater discharge, while slag yield is also cut down by 94%, reducing energy consumption by approximately 25%, and achieving zero emission of heavy metal pollutants.
The painting workshop adopts world-class BASF high-throwing-power coating material, with B1B2+2K water-based varnish double-layer painting technology, significantly improving paint quality while protecting the environment too.
Assembly Workshop
Thanks to an automatic material supply and distribution system, AGV technology, automatic gluing robots and assembly technology, all components are efficiently and meticulously assembled in the Zhaoqing factory.
All the key torque joints of CBUs (Complete Built Up) are tested online through a powerful digital production system, ensuring 100% quality control of all key torque joints of the build-up.
Battery Pack Workshop
The pack workshop utilizes an AGV flexible production line, combining high-precision visual systems and robots to execute intelligent operations. The intelligent end-of-line testing system conducts comprehensive testing – including 198 offline tests and 89 battery performance tests - for every battery pack, including insulation, SOC performance and BMS function to ensure that every battery pack meets the industry-leading IP68 sealing protection requirements.
The Xpeng P7 will go through 18 vigorous quality control procedures. Each vehicle will also go through over 1,700 dynamic and static tests, and 18 simulated road condition tests for control, braking, comfort, sealing, and abnormal sound to guarantee its quality.
Zhaoqing Xpeng Motors Intelligent Industrial Park – At a Glance
- Total planned area: 3,000 acres (2 million square metres)
- Vehicle production facilities area: 1,500 acres (1 million square metres).
- Phase 1 construction: 900 acres (600,000 square metres)
- Foundation-laying: December 2017
- Construction completion: September 2019
- MIIT production license: received on 19 May 2020
- Industry 4.0 standards
- Five workshops
- 264 intelligent industrial robots
For more P7 videos and images please visit: https://drive.google.com/open?id=1mjds6n51HszTF5YhDcbaViucSwLjeiio
About XPENG Motors
Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/
Follow us on social media for latest Xpeng news:
Facebook Twitter LinkedIn YouTube Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005686/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
